US Stock MarketDetailed Quotes
NUVB Nuvation Bio
- 2.300
- +0.010+0.44%
Close Oct 1 16:00 ET
- 2.290
- -0.010-0.43%
Post 20:01 ET
769.99MMarket Cap-1036P/E (TTM)
2.350High2.240Low1.37MVolume2.290Open2.290Pre Close3.14MTurnover0.59%Turnover RatioLossP/E (Static)334.78MShares4.16052wk High2.99P/B533.93MFloat Cap0.95052wk Low--Dividend TTM232.14MShs Float15.230Historical High--Div YieldTTM4.80%Amplitude0.950Historical Low2.297Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Nuvation Bio Stock Forum
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
Nuvation Bio (NYSE: NUVB) announced positive pooled data from TRUST-I and TRUST-II studies evaluating taletrectinib, a next-generation ROS1 TKI for advanced ROS1-positive NSCLC. Key findings include:
- 89% tumor shr...
Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study
Responses were durable with long-term follow-up; 71% of TKI-naïve patients were still progression-free at two years
TRUST-I is one of t...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
NEWS
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
Nuvation Bio completes the acquisition of AnHeart Therapeutics, transforming into a late-stage global oncology company. Shareholders now own approximately 67% and 33% of NUVB, setting the stage for potential commercial success by 2025.
⇒ $137.5M deal at $20.42/sh 💰💰
⇒ strengthens portfolio in inflammatory & autoimmune diseases
⇒ Adds lead asset NX-13 (Ph2 trial UC)
$Nuvation Bio (NUVB.US)$ to acquire AnHeart Therapeutics
⇒ all-stock transaction
⇒ transforms NUVB into late-stage global oncology company
⇒ Includes taletrectinib with ongoing trials NSCLC)
$Novo-Nordisk A/S (NVO.US)$ to acquire Cardior Pharmaceuticals
⇒ 1.025 B euros deal 💰💰
⇒ strengthens pi...
• $Axsome Therapeutics (AXSM.US)$ +39.1% (received from FDA proposed labeling for the its AXS-05 product candidate with respect to its New Drug Application for AXS-05 for the treatment of major depressive disorder)
• $Capricor Therapeutics (CAPR.US)$ +4% (announces statistically significant clinical benefits in skeletal muscle function in non-ambulant duchenne muscular dystrophy patients treated with CAP-1002 in HOPE-2 Open L...
• $Companhia Brasileira De Distribuicao (CBD.US)$ : BofA Securities Upgrades to Buy from Underperform - PT $5.25
• $Hexcel (HXL.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $65 (from $45)
• $IPG Photonics (IPGP.US)$ : Citigroup Upgrades to Buy from Neutral - PT $157
• $Livent (LTHM.US)$ : Cowen Upgrades to Outperform from Market Perform - PT $33 (from $25)
• $Premier (PINC.US)$ : Piper Sandler Upgrades to Overweight from Neutral - PT $45 (from $...
No comment yet